<DOC>
	<DOCNO>NCT01480076</DOCNO>
	<brief_summary>The primary objective study assess effect long-term treatment prolonged-release fampridine ( BIIB041 ) 10 mg twice daily physical component scale ( PCS ) Short Form 36 Health Status Questionnaire ( SF-36 ) report treatment responder . The secondary objective study compare change PCS SF-36 treatment responder non-responders , evaluate change baseline additional quality life measure among treatment responder well change baseline treatment responder versus non-responders assess safety tolerability prolonged-release fampridine 10 mg twice daily .</brief_summary>
	<brief_title>Open-Label Study Assess Effect Long-Term Prolonged-Release Fampridine ( BIIB041 ) Quality Life Reported Participants With Multiple Sclerosis</brief_title>
	<detailed_description>This study 2 component : 4-week run-in period participant treat prolonged-release fampridine undergo subjective objective assessment walk ability , result use determine respond study treatment , observational period , treatment responder continue prolonged-release fampridine treatment . The participant meet criterion continue study treatment offer opportunity continue study participation continue prolonged-release fampridine treatment .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>4-Aminopyridine</mesh_term>
	<criteria>Key Ability understand purpose risk study provide sign date informed consent authorization use protect health information accordance national local subject privacy regulation . Must diagnosis primaryprogressive , secondaryprogressive , progressiveremitting , relapsingremitting multiple sclerosis ( MS ) per revise McDonald Committee criterion ( [ Polman et al , 2011 ] ) define Lublin Reingold [ Lublin Reingold 1996 ] least 3 month duration . Have walk impairment determine Investigator . Able perform Timed 25foot Walk Test without walk aid . Female subject childbearing potential must practice effective contraception study willing able continue contraception 30 day last dose study treatment . Able understand comply requirement protocol . Key Known allergy pyridinecontaining substance inactive ingredient prolongedrelease fampridine tablet . Any history seizure , epilepsy , convulsive disorder , exception febrile seizures childhood . An estimated creatinine clearance &lt; 80 mL/minute . Subject need take medicinal product inhibitor organic cation transporter 2 ( OCT2 [ e.g. , cimetidine ] ) . Female subject currently pregnant consider become pregnant participate study . Female subject currently breastfeed . Previous exposure fampridine . NOTE : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Quality Life</keyword>
	<keyword>Multiple Sclerosis</keyword>
</DOC>